CClinicalTrials.gg
CompletedNCT06322615Updated Oct 29, 2025

Acupressure for Reducing Anxiety in Patients Undergoing Chemotherapy

An interventional study of Acupressure Therapy and Educational Intervention in Hematopoietic and Lymphatic System Neoplasm and Malignant Solid Neoplasm, sponsored by Mayo Clinic. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-29.

Sponsored by Mayo Clinic · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Aug 2023, registered Mar 2024).
Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This clinical trial evaluates whether acupressure is helpful to reduce anxiety related to chemotherapy. Anxiety is experienced by many patients with cancer. Anxiety can be related to chemotherapy and may contribute to other symptoms, such as nausea and poor quality of life. Some patients diagnosed with cancer express interest in non-medicinal ways to manage symptoms. Acupressure is a noninvasive intervention that can be used for many different symptoms. Acupressure is well tolerated with minimal reports of adverse reactions, making it a good choice for patients with cancer. This study may help researchers learn whether acupressure is useful for managing anxiety in patients undergoing chemotherapy.

Read the detailed description

PRIMARY OBJECTIVES:

I. Evaluate the feasibility of a nurse- and patient-applied acupressure intervention for patients with anxiety associated with active cancer-directed therapy.

II. Patient-reported changes in acute anxiety associated with both the nurse and self-led acupressure interventions will be ascertained.

OUTLINE:

Patients undergo acupressure over 15-120 seconds at a time for up to 15 minutes. After completion of the session, patients may optionally receive an education session on using acupressure at home.

After completion of study intervention, patients who opted to receive education about using acupressure at home are followed up at 1 week.

02

Conditions studied

  • Hematopoietic and Lymphatic System Neoplasm
  • Malignant Solid Neoplasm
03

In context

Lead sponsor

Mayo Clinic is the lead sponsor of 3,218 studies on the registry; 670 are open to participants now.

Of its 445 completed or terminated interventional studies of FDA-regulated products, 313 (70%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Be over 18 years of age
  • Be actively undergoing chemotherapy in the Mayo Clinic chemotherapy unit
  • Report anxiety as a 1 or higher, on a scale from 0 (no anxiety) to 4 (severe anxiety)
  • Be willing to undergo a short acupressure session

Exclusion criteria

Exclusion Criteria:

  • Does not meet the inclusion criteria
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Supportive Care (acupressure)

    Patients undergo acupressure over 15-120 seconds at a time for up to 15 minutes. After completion of the session, patients may optionally receive an education session on using acupressure at home.

    Procedure: Acupressure Therapy · Other: Educational Intervention · Other: Electronic Health Record Review · Other: Questionnaire Administration

Interventions

  • ProcedureAcupressure Therapy

    Undergo acupressure

    Also known as: Acupressure, Ischemic Compression

  • OtherEducational Intervention

    Receive education session about using acupressure at home

    Also known as: Education for Intervention, Intervention by Education, Intervention through Education, Intervention, Educational

  • OtherElectronic Health Record Review

    Ancillary studies

  • OtherQuestionnaire Administration

    Ancillary studies

06

What researchers measure

Primary outcomes

  1. Number of patients approached about undergoing acupressure intervention (Feasibility)

    Assessed by the number of patients approached about undergoing acupressure intervention.

    Time frame: Up to 1 year

  2. Number of patients interested in the initial acupressure intervention in the chemotherapy unit (Feasibility)

    Assessed by the number of patients who express interest in the initial acupressure intervention in the chemotherapy unit.

    Time frame: Up to 1 year

  3. Number of patients interested in the home acupressure intervention (Feasibility)

    Assessed by the number of patients who express interest in the home acupressure intervention.

    Time frame: Up to 1 year

  4. Time taken for each nurse-led acupressure intervention in the chemotherapy unit (Feasibility)

    Assess by the time recorded for ach nurse-led acupressure intervention in the chemotherapy unit.

    Time frame: Up to 1 year

  5. Patient-reported changes in acute anxiety

    Assessed with a brief anxiety questionnaire that inquires about the three different domains of anxiety: cognitive symptoms, emotional symptoms, and physical symptoms. Seven questions are answered using 11-point (0-10) scales with different values assigned to the scale per question (e.g. 0=no anxiety/10=worst possible anxiety or 0=strongly disagree/10=strongly agree).

    Time frame: At baseline, after a one-time nurse-administered acupressure session, and after one week of self-administered acupressure sessions

07

Study locations

1 site
  • Mayo Clinic in Rochester
    Rochester, Minnesota 55905, United States
08

References and documents

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06322615
Lead sponsor
Mayo Clinic
Responsible party
Sponsor
First posted
Mar 21, 2024
Start date
Aug 8, 2023
Primary completion
Jan 29, 2024
Completion
Feb 1, 2024
Last update
Oct 29, 2025

Study contacts

Laura S. Rhee, D.O.
principal investigator · Mayo Clinic in Rochester

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion